Monthly Archives: October 2020

Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer

New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso®, which received FDA Fast Track Designation earlier in 2020

Read More

Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Approval of new name marks important branding milestone and aligns with the program’s overall progress

Read More

Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing

Mr. Chapdelaine’s promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials

Read More

Genprex to Present at Zooming with LD Micro on October 14, 2020

Genprex’s President and Chief Executive Officer, Rodney Varner, will be delivering the company’s corporate presentation followed by a Q&A session with participants.

Read More

Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day.

Read More